Cord blood stem cells

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 413-418

  Wagner, John E ^a   Kurtzberg, Joanne ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; MULTIPLE REGRESSION; PRIORITY JOURNAL; REVIEW; RISK; STATISTICAL ANALYSIS; UMBILICAL CORD BLOOD;

EID: 0030777628     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00009     Document Type: Review

References (14)

1. Gluckman E, Broxmeyer HE, Auerbach AD, et al.: Hematopoietic reconstitution In a patient with Fanconi anemia by means of umbilical cord blood from an HLA-identical sibling. New Engl J Med 1989, 321:1174-1178. A report of the results of the first umbilical cord blood transplantation documenting hematopoietic reconstitution and donor cell engraftment using this stem cell source.
2. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E: Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995, 346:214-219. [Plenary session presentation at the American Society of Hematology, St. Louis, MO]. A report on the series on umbilical cord blood transplantation documenting high rate of engraftment, low risk of graft-versus-host disease, and survival in 44 recipients of sibling donor umbilical cord blood. Gluckman et al. [3] extend those results documenting outcomes in larger numbers of patients.
3. Gluckman E, Rocha V, Boyer Chammard A, Locatelli F, Arcese W, Souillet G, for the EuroCord Transplant Group: Results of cord blood transplants in Europe [abstract]. Blood 1996, 88:485a.
4. Falkenberg JH, van Luxemburg-Heijs SA, Lim FT, Kanhai HH, Willemze R: Umbilical cord blood contains normal frequencies of cytotoxic T-lymphocyte precursors and helper T-lymphocyte precursors against noninherited maternal antigens and noninherited paternal antigens. Ann Hematol 1996, 72:260-264.
5. Socié G, Gluckman E, Carosella E, Brossard Y, Lafon C, Brison O: Search for maternal cells in human umbilical cord blood by polymerase chain reaction by amplification of two minisatellite sequences. Blood 1994, 83:340-344.
6. Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA: Detection of maternal cells in human umbilical cord blood using fluorescence In situ hybridization. Blood 1995, 86:2829-2832.
7. Scaradavou A, Carrier C, Mollen N, Stevens C, Rubinstein P: Detection of maternal DNA in placental/umbilical cord blood by locus specific amplification of the non-inherited maternal HLA gene. Blood 1996, 88:1494-1500.
8. Kogler G, Gobel U, Somville T, Enczmann J, Arkestein G, Wernet P: Simultaneous genotypic and immunophenotypic analysis of interphase cells for the detection of contaminating maternal cells in cord blood and their respective CFU-GM and BFU-E. J Hematother 1992, 2:235-236.
9. Abecasis MM, Machado AM, Boavida G, Silva MG, Lucio P, Ambrosio A, Jorge ML: Haploidentical cord blood transplant contaminated with maternal T cells in a patient with advanced leukaemia. Bone Marrow Transplant 1996, 17:891-895. Explanation for the low risk of graft-versus-host disease observed after umbilical cord blood transplantation cannot be explained by CTLp and HTLp frequencies, particularly in the setting of haploidentical transplantation [4•]. Further, the presence of maternal cell contamination, as reported by Socié et al. [5•], Hall et al. [6•], Scaradavou et al. [7•], Kogler et al. [8•], and Abecasis et al. [9•], does not appear to increase the risk of graft-versus-host disease.
10. Rubinstein P, Carrier C, Adamson J, Migliaccio A, Berkowitz R, Kurtzberg J, Scaradavou A, Stevens C: New York Blood Center's program for unrelated placental/umbilical cord blood (PCB) transplantation: 243 transplants in the first 3 years [abstract]. Blood 1996, 88:142a. [Plenary Session presentation at the American Society of Hematology, Orlando, FL].
11. Migliaccio AR, Adamson JW, Rubinstein P, Stevens C: Placental/cord blood stem cell transplantation: correlation between the progenitor cell dose and time to myeloid engraftment in 55 unrelated transplants [abstract]. Blood 1996, 88:286a.
12. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, et al.: Outcome of cord blood transplantation from related and unrelated donors. New Engl J Med 1997, 337:373-381.
13. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med 1996, 335:157-166.
14. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies S, Ramsay NKC, McGlave P, Sender L, Cairo CS: Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802. A report [10••] of the clinical results in terms of rate of engraftment, risk of graft-versus-host disease, and survival for the first 243 unrelated donor umbilical cord blood transplants facilitated by the New York Blood Center with Migliaccio et al. [11•] detailing the correlation between CFU-GM and days to neutrophil recovery. Gluckman et al. [12••] provides a detailed analysis of outcomes and risk factors for sibling and unrelated donor umbilical cord blood tranplants performed in Europe, and Kurtzberg et al. [13••] and Wagner et al. [14••] provide the details on the two largest institutional series reported to date.